Altimmune, Inc. (NASDAQ:ALT) Short Interest Up 15.4% in February

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 11,550,000 shares, a growth of 15.4% from the January 31st total of 10,010,000 shares. Based on an average daily trading volume, of 12,000,000 shares, the days-to-cover ratio is presently 1.0 days.

Altimmune Trading Down 0.1 %

Shares of ALT stock opened at $12.09 on Friday. Altimmune has a fifty-two week low of $2.09 and a fifty-two week high of $14.84. The stock has a 50 day moving average price of $10.39 and a two-hundred day moving average price of $5.77.

Wall Street Analysts Forecast Growth

ALT has been the subject of a number of recent research reports. B. Riley restated a "buy" rating and issued a $20.00 target price on shares of Altimmune in a research report on Tuesday, February 13th. The Goldman Sachs Group initiated coverage on Altimmune in a research report on Wednesday, January 24th. They issued a "neutral" rating and a $13.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Altimmune in a research report on Friday, December 1st.

Hedge Funds Weigh In On Altimmune

Several hedge funds have recently made changes to their positions in ALT. JPMorgan Chase & Co. increased its stake in shares of Altimmune by 65.8% during the first quarter. JPMorgan Chase & Co. now owns 307,589 shares of the company's stock valued at $1,873,000 after buying an additional 122,021 shares during the period. MetLife Investment Management LLC increased its stake in shares of Altimmune by 65.5% during the first quarter. MetLife Investment Management LLC now owns 21,184 shares of the company's stock valued at $129,000 after buying an additional 8,385 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of Altimmune during the first quarter valued at approximately $1,108,000. Vanguard Group Inc. increased its stake in shares of Altimmune by 4.8% during the first quarter. Vanguard Group Inc. now owns 1,816,915 shares of the company's stock valued at $11,065,000 after buying an additional 83,160 shares during the period. Finally, XTX Topco Ltd increased its stake in shares of Altimmune by 33.2% during the first quarter. XTX Topco Ltd now owns 19,665 shares of the company's stock valued at $120,000 after buying an additional 4,898 shares during the period. 66.99% of the stock is owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.